Drug Trial Radar · NCT07367971
Drug-Drug Interaction Study of ABP-671 in Gout Patients
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
22
Actual
Start
Jan 23, 2026
Primary completion
Aug 19, 2026
Study completion Aug 19, 2026
Sponsor
- Lead sponsor
- Atom Therapeutics Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.
Conditions
- Gout Chronic
- Gout
- DDI (Drug-Drug Interaction)
Interventions
ABP-671 plus allopurinolDrug
All subjects undergo three sequential 7-day periods: Period 1 (Day 1-7): Allopurinol; Period 2 (Day 1-7): Allopurinol Plus ABP-671; Period 3 (Day 1-7): ABP-671;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum plasma concentration (Cmax) of allopurinolTime frame: Base line, through Day1, Day 7,Day8,D14,D15,D21
- Area under the plasma concentration-time curve over the dosing interval (AUC) of allopurinolTime frame: Base line, through Day1, Day 7,Day8,D14,D15,D21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Wakefield Clinical Research
Cary, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.